201. Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome
- Author
-
Jolanta Kupryjanczyk, Nicolas Wentzensen, Simon A. Gayther, Celeste Leigh Pearce, Susanne K. Kjaer, Irene Orlow, Zachary C. Fogarty, Evelyn Despierre, Yukie Bean, Georgia Chenevix-Trench, Robert A. Vierkant, Agnieszka Dansonka-Mieszkowska, Lene Lundvall, Jonathan Tyrer, Joellen M. Schildkraut, Izabela Ziolkowska-Seta, Diana Eccles, Iwona K. Rzepecka, Catherine M. Phelan, Hoda Anton Culver, Jennifer A. Doherty, Ignace Vergote, Daniel W. Cramer, Matthias W. Beckmann, Susan J. Ramus, Paul D.P. Pharoah, Honglin Song, Ursula Eilber, Galina Lurie, Jan Lubinski, Philipp Harter, Sandrina Lambrechts, David Van DenBerg, James Paul, Ellen L. Goode, Claus Høgdall, Janusz Menkiszak, James M. Flanagan, Christine Walsh, Julie M. Cunningham, Jenny Lester, Kristin L. White, Elisa V. Bandera, Robert S. Brown, Allan Jensen, Stanley B. Kaye, Matthew S. Block, Sharon E. Johnatty, Louise A. Brinton, Estrid Høgdall, Malcolm C. Pike, Thomas A. Sellers, Arif B. Ekici, Andreas du Bois, Hannah P. Yang, Aleksandra Gentry-Maharaj, Cezary Cybulski, Jenny Chang-Claude, Valerie McGuire, Marc T. Goodman, Anna deFazio, Ian G. Campbell, Argyrios Ziogas, Alexander Hein, Lisa E. Paddock, Usha Menon, Brooke L. Fridley, Mary Anne Rossing, Douglas A. Levine, Bridget Charbonneau, Andrew Berchuck, Jacek Gronwald, Alice S. Whittemore, Joseph H. Rothstein, Anja Rudolph, Weiva Sieh, Kimberly R. Kalli, Sara H. Olson, Allison F. Vitonis, Anna H. Wu, Tanja Pejovic, Peter A. Fasching, Florian Heitz, Beth Y. Karlan, Diether Lambrechts, Kathryn L. Terry, Ira Schwaab, and Montserrat Garcia-Closas
- Subjects
Oncology ,medicine.medical_specialty ,Genotype ,Epidemiology ,Single-nucleotide polymorphism ,Polymorphism, Single Nucleotide ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,SNP ,Humans ,Genetic Predisposition to Disease ,Survival analysis ,Genetic Association Studies ,030304 developmental biology ,Genetic association ,Proportional Hazards Models ,Ovarian Neoplasms ,0303 health sciences ,Polymorphism, Genetic ,Proportional hazards model ,business.industry ,Cancer ,medicine.disease ,Prognosis ,Survival Analysis ,3. Good health ,030220 oncology & carcinogenesis ,Immunology ,Female ,business ,Ovarian cancer - Abstract
Background: Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNP) previously associated with ovarian cancer recurrence or survival, specifically in angiogenesis, inflammation, mitosis, and drug disposition genes. Methods: Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000-observed person-years and 4,478 deaths. Cox proportional hazards models were used to examine the association between candidate SNPs and ovarian cancer recurrence or survival with and without adjustment for key covariates. Results: We observed no association between genotype and ovarian cancer recurrence or survival for any of the SNPs examined. Conclusions: These results refute prior associations between these SNPs and ovarian cancer outcome and underscore the importance of maximally powered genetic association studies. Impact: These variants should not be used in prognostic models. Alternate approaches to uncovering inherited prognostic factors, if they exist, are needed. Cancer Epidemiol Biomarkers Prev; 22(5); 987–. ©2013 AACR.
- Published
- 2013
- Full Text
- View/download PDF